<DOC>
	<DOCNO>NCT01959698</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose carfilzomib give together rituximab , ifosfamide , carboplatin , etoposide see well work treat patient stage I-IV diffuse large B-cell lymphoma return ( relapse ) respond treatment ( refractory ) . Carfilzomib may stop growth cancer cell block enzymes need cell growth . Monoclonal antibody , rituximab , may block cancer growth different way target certain cell . Drugs use chemotherapy , ifosfamide , carboplatin , etoposide , also work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving carfilzomib rituximab , ifosfamide , carboplatin , etoposide may better treatment diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>Carfilzomib , Rituximab , Ifosfamide , Carboplatin , Etoposide Treating Patients With Relapsed Refractory Stage I-IV Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate maximum tolerate dose ( MTD ) examine dose-limiting toxicity carfilzomib administer combination rituximab , ifosfamide , carboplatin , etoposide ( C-R-ICE ) patient relapsed/refractory diffuse large B-cell lymphoma ( DLBCL ) . ( Phase I ) II . To assess toxicity dose regimen use Cancer Therapy Evaluation Program ( CTEP ) National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE version 4.0 ) . ( Phase I ) III . To evaluate safety carfilzomib ( give maximum tolerate dose [ MTD ] determine Phase I study ) combination R-ICE salvage therapy relapsed/refractory DLBCL patient . ( Phase II ) IV . To achieve overall response rate ( complete response [ CR ] partial response [ PR ] ) 70 % 3 cycle C-R-ICE patient age 18 75 relapsed/refractory cluster differentiation ( CD ) 20-positive DLBCL previously treat rituximab-based immunochemotherapy ( e.g. , rituximab , cyclophosphamide , doxorubicin , vincristine [ vincristine sulfate ] , prednisone [ R-CHOP ] , rituximab , etoposide , prednisone , vincristine , cyclophosphamide , doxorubicin [ REPOCH ] , rituximab , cyclophosphamide , vincristine , doxorubicin , dexamethasone , methotrexate , cytarabine [ R-HyperCVAD ] , etc . ) induction . ( Phase II ) SECONDARY OBJECTIVES : I . To determine feasibility successful mobilization autologous stem cell ( i.e. , minimum 2 x 10^6 CD34+ cells/kg collect ) use autologous stem cell transplant ( ASCT ) . II . To determine toxicity associate C-R-ICE salvage therapy . III . To determine time progression ( TTP ) , progression-free survival ( PFS ) , overall survival ( OS ) follow ASCT ; disease-free survival CR patient . IV . To determine pharmacokinetics/pharmacodynamics relationship carfilzomib 's degree proteasome inhibition response rate along time course thrombocytopenia . V. To study difference clinical outcome germinal center B-cell-like ( GCB ) non-GCB relapsed/refractory DLBCL follow therapy carfilzomib R-ICE . VI . Correlative translational research study include : phenotypic/genotypic analysis functional activity ( i.e. , antibody-dependent cellular cytotoxicity [ ADCC ] complement-mediated cytotoxicity [ CMC ] ) patient 's peripheral blood mononuclear `` effector '' cell ( PBMC ) , well ex vivo analysis sensitivity primary tumor cell various combination carfilzomib versus bortezomib +/- rituximab ; enzymatic assay chymotrypsin-like activity determine degree proteasome inhibition primary DLBCL patient sample patient PBMC specimen ; explorative analysis identify potential factor predictive response therapy perform . OUTLINE : This phase I , dose-escalation study carfilzomib , follow phase II study . Patients receive carfilzomib intravenously ( IV ) 10-30 minute day 1 , 2 , 8 , 9 ; rituximab IV 3-8 hour day 3 ; etoposide IV 1 hour day 4-6 ; carboplatin IV 1 hour day 5 ; ifosfamide IV 24 hour day 5 . Treatment repeat every 21-28 day 3 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 4 month 1 year , every 6 month 2 year , annually 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histological confirmation relapsed/refractory CD20 positive diffuse large Bcell lymphoma A tissue block unstained slide submit Roswell Park Cancer Institute ( RPCI ) Pathology Department central pathology review ; addition immunohistochemistry ( IHC ) CD20 , antigen identify monoclonal antibody Ki67 ( Ki67 ) , CD10 , Bcell chronic lymphocytic leukemia/lymphoma 2 ( Bcl2 ) , Bcl6 , melanoma associate antigen ( mutate ) 1 ( MUM1 ) stain perform Cell origin determine accord Han 's algorithm Ann Arbor stage I stage IV DLBCL time relapsed/refractory disease eligible Measurable assessable disease require ; measurable tumor size ( least one node measure 2.25 cm^2 bidimensional measurement ) per compute tomography ( CT ) scan , radiological study , and/or physical exam Patients must receive least 1 prior rituximabbased immunochemotherapy ( e.g. , RCHOP , REPOCH , etc . ) &gt; = 2 week since major surgery Patients must significant toxicity associate prior surgery , radiation therapy , chemotherapy , immunotherapy , per principal investigator ( PI ) discretion Life expectancy &gt; = 3 month Karnofsky score ( KS ) &gt; = 50 Serum alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) = &lt; 3.5 time upper limit normal within 14 day prior start therapy Absolute neutrophil count ( ANC ) &gt; = 1.0 x 10^9/L within 14 day prior start therapy* Hemoglobin &gt; = 8 g/dL ( 80 g/L ) within 14 day prior randomization ( subject may receive red blood cell [ RBC ] transfusion accordance institutional guideline ) * Platelet count &gt; = 50 x 10^9/L ( &gt; = 20 x 10^9/L lymphoma involvement pretreatment bone marrow find ) within 14 day prior start therapy* *Note : If patient cytopenia due bone marrow involvement , requirement applicable Serum creatinine = &lt; 1.5 mg/dL ; creatinine &gt; 1.5 mg/dL creatinine clearance must &gt; 60 mL/min within 7 day prior treatment either measure calculated use standard Cockcroft Gault formula Written inform consent accordance federal , local , institutional guideline Females childbearing potential ( FCBP ) must agree ongoing pregnancy test practice contraception ; woman become pregnant suspect pregnant partner participate study , inform treat physician immediately Male subject must agree practice contraception No known hypersensitivity murine product Patients must normal baseline cardiac function base upon echocardiogram gate blood pool scan ( multigated acquisition scan [ MUGA ] ) ejection fraction &gt; = 50 % Patients test positive hepatitis C ( HepC ) antibody ( Ab ) eligible provide follow criterion meet : bilirubin = &lt; 2 x upper limit normal ; ALT/AST = &lt; 3 x upper limit normal ; clinical evaluation rule cirrhosis Specific guideline follow regard inclusion relapsed/refractory DLBCL base hepatitis B serological testing follow : Hepatitis B surface antigen ( HBsAg ) negative , hepatitis B core antibody ( HBcAb ) negative , hepatitis B surface antibody ( HBsAb ) positive patient eligible Patients test positive HBsAg ineligible ( regardless hepatitis B serology ) Patients HBsAg negative , HBcAb positive ( regardless HBsAb status ) hepatitis B virus ( HBV ) deoxyribonucleic acid ( DNA ) test do protocol eligibility determine follow : If HBV DNA positive , subject exclude study If HBV DNA negative , subject may include must undergo least every 2 month HBV DNA polymerase chain reaction ( PCR ) test start treatment throughout duration treatment course Patients nonHodgkin lymphoma ( NHL ) DLBCL ; include `` transform '' DLBCL Known seropositive human immunodeficiency virus ( HIV ) ; HIV test require entry protocol , require patient perceive risk Positive serology HBV define positive test HBsAg ; addition , negative HBsAg HBcAb positive ( regardless HBsAb status ) , HepB DNA test perform positive subject exclude Patients symptomatic brain involvement Peripheral neuropathy grade 2 great severity define National Cancer Institute 's ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 ; patient grade 2 high ( NCICommon Toxicity Criteria [ CTC ] ) neuropathy Myocardial infarct within 6 month enrollment , New York Heart Association ( NYHA ) class II great heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , clinically significant pericardial disease , electrocardiographic evidence acute ischemia Uncontrolled intercurrent illness include , limited , active infection , poorly control hypertension , diabetes mellitus serious medical psychiatric condition could interfere adherence completion study Pregnant breastfeeding Patient receive investigational drug within 4 week enrollment Chemotherapy within 3 week first schedule study treatment Less 2years disease free another primary malignancy ( squamous basal cell carcinoma skin , `` insitu '' carcinoma cervix breast , superficial bladder carcinoma , previously treat localized prostate cancer normal prostatespecific antigen [ PSA ] level ) ; patient consider `` currently active '' malignancy complete anticancer therapy , consider physician less 30 % risk relapse least 2 year lapse Major surgery , diagnostic surgery , within 2 week Known history allergy Captisol ( cyclodextrin derivative use solubilize carfilzomib ) Medical condition require chronic use high dose systemic corticosteroid ( i.e. , dose prednisone high 10 mg/day equivalent ) Prior highdose chemotherapy ( HDC ) ASCT Active central nervous system ( CNS ) disease define symptomatic meningeal lymphoma know CNS parenchymal lymphoma ; lumbar puncture demonstrate DLBCL time registration study exclusion study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>